# DIADEMA PARTNERS LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 2026172. Source: https://holderbook.com/funds/2026172-diadema-partners-lp/

- Reported value: $791.3M
- Positions: 116
- Weight of the ten largest: 50.4%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| ABIVAX SA | [ABVX](https://holderbook.com/stocks/ABVX/) | $101.8M | 163,644 | 12.9% | 4 |
| VIKING THERAPEUTICS INC | [VKTX](https://holderbook.com/stocks/VKTX/) | $78.5M | 441,808 | 9.9% | 6 |
| BRISTOL-MYERS SQUIBB CO | [BMY](https://holderbook.com/stocks/BMY/) | $53.6M | 0 | 6.8% | 1 |
| UNITED THERAPEUTICS CORP DEL | [UTHR](https://holderbook.com/stocks/UTHR/) | $28.7M | 52,989 | 3.6% | 3 |
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $26.1M | 139,218 | 3.3% | 5 |
| UNIQURE NV | [QURE](https://holderbook.com/stocks/QURE/) | $24.6M | 0 | 3.1% | 7 |
| NOVARTIS AG | [NVS](https://holderbook.com/stocks/NVS/) | $23.5M | 0 | 3.0% | 1 |
| KODIAK SCIENCES INC | [KOD](https://holderbook.com/stocks/KOD/) | $21.9M | 218,117 | 2.8% | 4 |
| CAPRICOR THERAPEUTICS INC | [CAPR](https://holderbook.com/stocks/CAPR/) | $20.8M | 0 | 2.6% | 7 |
| COGENT BIOSCIENCES INC | [COGT](https://holderbook.com/stocks/COGT/) | $19.1M | 493,664 | 2.4% | 7 |
| BRIDGEBIO PHARMA INC | - | $18.6M | 250,000 | 2.4% | 2 |
| CORCEPT THERAPEUTICS INC | [CORT](https://holderbook.com/stocks/CORT/) | $17.9M | 0 | 2.3% | 6 |
| BIOMARIN PHARMACEUTICAL INC | [BMRN](https://holderbook.com/stocks/BMRN/) | $17.9M | 312,846 | 2.3% | 6 |
| KYMERA THERAPEUTICS INC | [KYMR](https://holderbook.com/stocks/KYMR/) | $17.2M | 0 | 2.2% | 1 |
| SUMMIT THERAPEUTICS INC | [SMMT](https://holderbook.com/stocks/SMMT/) | $16.3M | 60,000 | 2.1% | 1 |
| HIMS & HERS HEALTH INC | [HIMS](https://holderbook.com/stocks/HIMS/) | $13.6M | 0 | 1.7% | 1 |
| REPLIMUNE GROUP INC | [REPL](https://holderbook.com/stocks/REPL/) | $13.3M | 0 | 1.7% | 7 |
| BIOGEN INC | [BIIB](https://holderbook.com/stocks/BIIB/) | $13.0M | 0 | 1.6% | 1 |
| ELI LILLY & CO | [LLY](https://holderbook.com/stocks/LLY/) | $12.0M | 0 | 1.5% | 6 |
| INCYTE CORP | [INCY](https://holderbook.com/stocks/INCY/) | $11.9M | 0 | 1.5% | 4 |
| EDGEWISE THERAPEUTICS INC | [EWTX](https://holderbook.com/stocks/EWTX/) | $11.1M | 272,214 | 1.4% | 3 |
| ARCUS BIOSCIENCES INC | [RCUS](https://holderbook.com/stocks/RCUS/) | $10.7M | 223,810 | 1.4% | 2 |
| BIONTECH SE | [BNTX](https://holderbook.com/stocks/BNTX/) | $9.3M | 0 | 1.2% | 1 |
| CORBUS PHARMACEUTICALS HLDGS | [CRBP](https://holderbook.com/stocks/CRBP/) | $8.8M | 301,264 | 1.1% | 2 |
| VAXCYTE INC | [PCVX](https://holderbook.com/stocks/PCVX/) | $8.5M | 45,071 | 1.1% | 7 |
| BIOAGE LABS INC | [BIOA](https://holderbook.com/stocks/BIOA/) | $8.5M | 146,334 | 1.1% | 3 |
| IMMUNOCORE HLDGS PLC | [IMCR](https://holderbook.com/stocks/IMCR/) | $8.1M | 254,863 | 1.0% | 6 |
| 4D MOLECULAR THERAPEUTICS IN | [FDMT](https://holderbook.com/stocks/FDMT/) | $7.6M | 571,107 | 1.0% | 1 |
| NOVO-NORDISK A S | [NVO](https://holderbook.com/stocks/NVO/) | $7.5M | 100,000 | 0.9% | 6 |
| SELLAS LIFE SCIENCES GROUP I | [SLS](https://holderbook.com/stocks/SLS/) | $7.4M | 0 | 0.9% | 5 |
| MODERNA INC | [MRNA](https://holderbook.com/stocks/MRNA/) | $7.0M | 0 | 0.9% | 2 |
| CORVUS PHARMACEUTICALS INC | [CRVS](https://holderbook.com/stocks/CRVS/) | $6.4M | 294,811 | 0.8% | 4 |
| MONTE ROSA THERAPEUTICS INC | [GLUE](https://holderbook.com/stocks/GLUE/) | $6.0M | 78,391 | 0.8% | 3 |
| ALUMIS INC | [ALMS](https://holderbook.com/stocks/ALMS/) | $5.6M | 0 | 0.7% | 2 |
| ROYALTY PHARMA PLC | [RPRX](https://holderbook.com/stocks/RPRX/) | $5.6M | 0 | 0.7% | 1 |
| JOHNSON & JOHNSON | [JNJ](https://holderbook.com/stocks/JNJ/) | $5.6M | 22,000 | 0.7% | 3 |
| UNICYCIVE THERAPEUTICS INC | [UNCY](https://holderbook.com/stocks/UNCY/) | $5.1M | 303,676 | 0.6% | 2 |
| CELLDEX THERAPEUTICS INC NEW | [CLDX](https://holderbook.com/stocks/CLDX/) | $5.1M | 0 | 0.6% | 1 |
| BIOHAVEN LTD | [BHVN](https://holderbook.com/stocks/BHVN/) | $4.7M | 0 | 0.6% | 3 |
| VERA THERAPEUTICS INC | [VERA](https://holderbook.com/stocks/VERA/) | $4.6M | 57,608 | 0.6% | 1 |
| TENAX THERAPEUTICS INC | [TENX](https://holderbook.com/stocks/TENX/) | $4.5M | 0 | 0.6% | 3 |
| RELAY THERAPEUTICS INC | [RLAY](https://holderbook.com/stocks/RLAY/) | $4.3M | 230,677 | 0.5% | 1 |
| TG THERAPEUTICS INC | [TGTX](https://holderbook.com/stocks/TGTX/) | $4.2M | 0 | 0.5% | 7 |
| AMGEN INC | [AMGN](https://holderbook.com/stocks/AMGN/) | $3.8M | 102,701 | 0.5% | 1 |
| ZYMEWORKS INC | [ZYME](https://holderbook.com/stocks/ZYME/) | $3.7M | 142,132 | 0.5% | 6 |
| TAYSHA GENE THERAPIES INC | [TSHA](https://holderbook.com/stocks/TSHA/) | $3.6M | 522,619 | 0.4% | 1 |
| INTELLIA THERAPEUTICS INC | [NTLA](https://holderbook.com/stocks/NTLA/) | $3.4M | 0 | 0.4% | 4 |
| NURIX THERAPEUTICS INC | [NRIX](https://holderbook.com/stocks/NRIX/) | $2.9M | 121,539 | 0.4% | 1 |
| INDIVIOR PHARMACEUTICALS INC | [INDV](https://holderbook.com/stocks/INDV/) | $2.8M | 67,512 | 0.4% | 2 |
| INVENTIVA SA | [IVA](https://holderbook.com/stocks/IVA/) | $2.7M | 740,786 | 0.3% | 3 |
| ORUKA THERAPEUTICS INC | [ORKA](https://holderbook.com/stocks/ORKA/) | $2.6M | 27,799 | 0.3% | 1 |
| CYTOKINETICS INC | [CYTK](https://holderbook.com/stocks/CYTK/) | $2.6M | 0 | 0.3% | 2 |
| RELMADA THERAPEUTICS INC | [RLMD](https://holderbook.com/stocks/RLMD/) | $2.5M | 361,367 | 0.3% | 3 |
| ANNEXON INC | [ANNX](https://holderbook.com/stocks/ANNX/) | $2.2M | 27,516 | 0.3% | 3 |
| CELCUITY INC | [CELC](https://holderbook.com/stocks/CELC/) | $2.1M | 0 | 0.3% | 2 |
| SEPTERNA INC | [SEPN](https://holderbook.com/stocks/SEPN/) | $2.0M | 0 | 0.3% | 2 |
| CYBIN INC | [HELP](https://holderbook.com/stocks/HELP/) | $2.0M | 200,000 | 0.3% | 1 |
| VOYAGER THERAPEUTICS INC | [VYGR](https://holderbook.com/stocks/VYGR/) | $2.0M | 413,642 | 0.2% | 2 |
| CONTINEUM THERAPEUTICS INC | [CTNM](https://holderbook.com/stocks/CTNM/) | $2.0M | 119,733 | 0.2% | 1 |
| BICYCLE THERAPEUTICS PLC | [BCYC](https://holderbook.com/stocks/BCYC/) | $2.0M | 462,724 | 0.2% | 2 |
| VIRIDIAN THERAPEUTICS INC | [VRDN](https://holderbook.com/stocks/VRDN/) | $1.8M | 100,000 | 0.2% | 1 |
| MACROGENICS INC | [MGNX](https://holderbook.com/stocks/MGNX/) | $1.7M | 374,403 | 0.2% | 2 |
| PROQR THRAPEUTICS N V | [PRQR](https://holderbook.com/stocks/PRQR/) | $1.7M | 926,016 | 0.2% | 7 |
| ADMA BIOLOGICS INC | [ADMA](https://holderbook.com/stocks/ADMA/) | $1.7M | 0 | 0.2% | 1 |
| SPRUCE BIOSCIENCES INC | [SPRB](https://holderbook.com/stocks/SPRB/) | $1.6M | 30,000 | 0.2% | 2 |
| ARDELYX INC | [ARDX](https://holderbook.com/stocks/ARDX/) | $1.5M | 303,025 | 0.2% | 1 |
| CUE BIOPHARMA INC | [CUE](https://holderbook.com/stocks/CUE/) | $1.5M | 48,369 | 0.2% | 1 |
| MINERALYS THERAPEUTICS INC | [MLYS](https://holderbook.com/stocks/MLYS/) | $1.5M | 56,347 | 0.2% | 3 |
| EYEPOINT INC | [EYPT](https://holderbook.com/stocks/EYPT/) | $1.5M | 0 | 0.2% | 2 |
| PROTHENA CORP PLC | [PRTA](https://holderbook.com/stocks/PRTA/) | $1.5M | 149,482 | 0.2% | 1 |
| PHATHOM PHARMACEUTICALS INC | [PHAT](https://holderbook.com/stocks/PHAT/) | $1.4M | 129,950 | 0.2% | 2 |
| EVOLUS INC | [EOLS](https://holderbook.com/stocks/EOLS/) | $1.4M | 0 | 0.2% | 3 |
| SPYRE THERAPEUTICS INC | [SYRE](https://holderbook.com/stocks/SYRE/) | $1.3M | 15,000 | 0.2% | 1 |
| CORMEDIX INC | [CRMD](https://holderbook.com/stocks/CRMD/) | $1.3M | 0 | 0.2% | 4 |
| EDITAS MEDICINE INC | [EDIT](https://holderbook.com/stocks/EDIT/) | $1.3M | 0 | 0.2% | 1 |
| EQUILLIUM INC | [EQ](https://holderbook.com/stocks/EQ/) | $1.3M | 400,282 | 0.2% | 4 |
| PYXIS ONCOLOGY INC | [PYXS](https://holderbook.com/stocks/PYXS/) | $1.2M | 0 | 0.1% | 1 |
| XERIS BIOPHARMA HOLDINGS INC | [XERS](https://holderbook.com/stocks/XERS/) | $1.1M | 132,746 | 0.1% | 4 |
| PHARVARIS N V | [PHVS](https://holderbook.com/stocks/PHVS/) | $1.0M | 29,321 | 0.1% | 2 |
| HARMONY BIOSCIENCES HLDGS IN | [HRMY](https://holderbook.com/stocks/HRMY/) | $978.1K | 26,864 | 0.1% | 4 |
| CARTESIAN THERAPEUTICS INC | [RNAC](https://holderbook.com/stocks/RNAC/) | $907.1K | 87,057 | 0.1% | 1 |
| AQUESTIVE THERAPEUTICS INC | [AQST](https://holderbook.com/stocks/AQST/) | $892.7K | 0 | 0.1% | 1 |
| RIGEL PHARMACEUTICALS INC | [RIGL](https://holderbook.com/stocks/RIGL/) | $892.6K | 22,816 | 0.1% | 1 |
| ELICIO THERAPEUTICS INC | [ELTX](https://holderbook.com/stocks/ELTX/) | $829.3K | 0 | 0.1% | 1 |
| PRECIGEN INC | [PGEN](https://holderbook.com/stocks/PGEN/) | $771.2K | 135,293 | 0.1% | 2 |
| DEFINIUM THERAPEUTICS INC | [DFTX](https://holderbook.com/stocks/DFTX/) | $726.8K | 15,451 | 0.1% | 1 |
| PELTHOS THERAPEUTICS INC | [PTHS](https://holderbook.com/stocks/PTHS/) | $700.1K | 24,773 | 0.1% | 4 |
| PEPGEN INC | [PEPG](https://holderbook.com/stocks/PEPG/) | $671.9K | 373,284 | 0.1% | 2 |
| CG ONCOLOGY INC | [CGON](https://holderbook.com/stocks/CGON/) | $518.7K | 0 | 0.1% | 1 |
| ENLIVEN THERAPEUTICS INC | [ELVN](https://holderbook.com/stocks/ELVN/) | $507.5K | 10,000 | 0.1% | 2 |
| CONNECT BIOPHARMA HLDGS LTD | [CNTB](https://holderbook.com/stocks/CNTB/) | $468.8K | 196,985 | 0.1% | 2 |
| LARIMAR THERAPEUTICS INC | [LRMR](https://holderbook.com/stocks/LRMR/) | $447.2K | 146,637 | 0.1% | 2 |
| CELLECTAR BIOSCIENCES INC | [CLRB](https://holderbook.com/stocks/CLRB/) | $384.6K | 138,341 | 0.0% | 1 |
| FOGHORN THERAPEUTICS INC | [FHTX](https://holderbook.com/stocks/FHTX/) | $326.5K | 66,908 | 0.0% | 4 |
| AYTU BIOPHARMA INC | [AYTU](https://holderbook.com/stocks/AYTU/) | $319.4K | 148,546 | 0.0% | 4 |
| OCUGEN INC | [OCGN](https://holderbook.com/stocks/OCGN/) | $306.0K | 200,000 | 0.0% | 2 |
| INOVIO PHARMACEUTICALS INC | [INO](https://holderbook.com/stocks/INO/) | $302.7K | 0 | 0.0% | 3 |
| UROGEN PHARMA LTD | [URGN](https://holderbook.com/stocks/URGN/) | $262.6K | 7,137 | 0.0% | 7 |
| HERON THERAPEUTICS INC | [HRTX](https://holderbook.com/stocks/HRTX/) | $195.8K | 458,723 | 0.0% | 1 |
| TALPHERA INC | [TLPH](https://holderbook.com/stocks/TLPH/) | $158.2K | 153,563 | 0.0% | 3 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q3 2025 | +8.8% | +7.8% | +1.0% | 66% |
| Q1 2025 | -5.4% | -4.6% | -0.8% | 65% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $791.3M | 116 |
| Q1 2026 | $587.7M | 111 |
| Q4 2025 | $580.5M | 119 |
| Q3 2025 | $391.0M | 106 |
| Q2 2025 | $328.2M | 75 |
| Q1 2025 | $383.3M | 72 |
| Q4 2024 | $233.1M | 86 |